Sales of Novartis’ Prexige Suspended in U.K., Germany, Austria After EU Announces Safety Review
This article was originally published in The Pink Sheet Daily
Executive Summary
EU’s Article 107 procedure was prompted by U.K. sanctions imposed in August after two Australian patients died from liver damage.
You may also be interested in...
Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval
Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a development path forward for the COX-2 inhibitor
Novartis Eyes Liver Safety Biomarker As Potential Path To Prexige Approval
Novartis has identified a genetic sequence that may be a risk factor for serious liver injury in patients receiving Prexige (lumiracoxib), a finding that may signal a development path forward for the COX-2 inhibitor
EMEA Backs Conditional Marketing Of GSK’s Tykerb, Withdrawal Of Novartis’ Prexige In EU
GSK to supply additional data for breast cancer drug; panel okays generics for Roche’s CellCept.